Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
165 hedge funds and large institutions have $371M invested in Clovis Oncology, Inc. in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 32 closing their positions.
30% more capital invested
Capital invested by funds: $286M → $371M (+$85.1M)
25% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 32
4% more funds holding
Funds holding: 159 → 165 (+6)
5% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
43% less call options, than puts
Call options by funds: $19.3M | Put options by funds: $33.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.95M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.28M |
| 3 |
BlackRock
New York
|
+$6.53M |
| 4 |
Citigroup
New York
|
+$4.46M |
| 5 |
Rafferty Asset Management
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.7M |
| 3 |
AC
Armistice Capital
New York
|
-$10.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.65M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.95M |
CLVS Hedge Fund Activity: Q1 2021 in Review
165 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2021, worth a combined $371M — up 30% from $286M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CLVS positions and 32 closed out — a net gain of 8 holders — while 46 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.95M. The largest seller was State Street, cutting an estimated $31.1M.
- 165 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2021, up from 159 in Q4 2020.
- Funds reported $371M of Clovis Oncology, Inc. stock for Q1 2021, up 30% quarter-over-quarter.
- 40 funds opened new Clovis Oncology, Inc. positions in Q1 2021 and 32 closed out, a net change of +8 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2021 was Millennium Management, an estimated $8.95M added.
- The largest Clovis Oncology, Inc. seller in Q1 2021 was State Street, an estimated $31.1M sold.
Based on aggregated 13F filings for Q1 2021.